CRX-527 as a candidate adjuvant in a recombinant BCG-based malaria vaccine  

作　　者：Nor Munirah Zakaria Muhammad Adamu Abbas Rapeah Suppian 

机构地区：[1]School of Health Sciences,Universiti Sains Malaysia,Health Campus,16150 Kubang Kerian,Kota Bharu,Kelantan,Malaysia [2]Department of Medical Microbiology and Parasitology,College of Health Sciences,Bayero University Kano,P.M.B.3011,BUK,Kano Nigeria

出　　处：《Asian Pacific Journal of Tropical Biomedicine》2024年第1期1-7,共7页亚太热带生物医学杂志（英文版）

基　　金：supported by the Ministry of Higher Education Malaysia for Fundamental Research Grant Scheme with Project Code:FRGS/1/2021/SKK06/USM/002/4.

摘　　要：Objective:To investigate the role of CRX-527,a Toll-like receptor 4 agonist,as the possible adjuvant for recombinant Mycobacterium bovis Bacillus Calmette-Guerin expressing merozoite surface protein 1C(BCG-MSP-1C).Methods:The mice were immunized with BCG and BCG-MSP-1C in the presence and absence of CRX-527.The untreated mice(injected with PBS-T80 only)were the negative control.The ability of CRX-527 to enhance IgG and its subclasses,as well as IL-4 and IFN-γproduction in the serum and spleen supernatant was evaluated using ELISA.Results:Mice immunized with BCG-MSP-1C exhibited the highest production of IgGs,IL-4 and IFN-γafter third immunization.In addition,CRX-527 further promoted the production of total IgG and IgG subclasses as well as IFN-γand IL-4 in the serum and splenocytes of immunized mice.Conclusions:CRX-527 has the potential as an adjuvant candidate for the candidate vaccines.Further study is needed to verify appropriate dosage for immunization and its efficacy.

关 键 词：CRX-527 BCG BCG-MSP-1C TLR-4 agonists Cytokine IgG MALARIA 

分 类 号：R531.3[医药卫生—内科学]